Ipsen Biopharmaceuticals, Inc.
NEWS
The deal will see Ipsen and Exicure collaborating to research, develop, and commercialize Spherical Nucleic Acids to treat AS and HD.
The drug, a novel dopamine D3-receptor antagonist, is being evaluated in Phase IIb trials for people with Parkinson’s disease who experience levodopa-induced dyskinesia.
The two companies studying the regimen for HCC, Exelixis and Ipsen, suggest the probability of reaching significance at the final analysis is low.
With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. Read on to see.
Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.
Biopharma and life sciences companies from around the globe share updates on their business practices and pipelines.
After four years as head of Sanofi’s vaccines division, David Loew is departing the pharma giant to take on a new role – chief executive officer of Paris-based Ipsen, effective July 1.
As the biopharma industry responds to the COVID-19 pandemic, some of the area’s companies are at the very frontlines of drug development against the disease, while others play supporting roles for the entire industry. Here’s a look.
Although some clinical trials are being slowed or halted, others are reporting out data. Here’s a look.
JOBS
IN THE PRESS